Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background & Aims: The cause of Crohn's disease (CD) is unknown, but the current hypothesis is that microbial or environmental factors induce gut inflammation in genetically susceptible individuals, leading to chronic intestinal inflammation. Case-control studies of patients with CD have cataloged alterations in the gut microbiome composition; however, these studies fail to distinguish whether the altered gut microbiome composition is associated with initiation of CD or is the result of inflammation or drug treatment.

Methods: In this prospective cohort study, 3483 healthy first-degree relatives (FDRs) of patients with CD were recruited to identify the gut microbiome composition that precedes the onset of CD and to what extent this composition predicts the risk of developing CD. We applied a machine learning approach to the analysis of the gut microbiome composition (based on 16S ribosomal RNA sequencing) to define a microbial signature that associates with future development of CD. The performance of the model was assessed in an independent validation cohort.

Results: In the validation cohort, the microbiome risk score (MRS) model yielded a hazard ratio of 2.24 (95% confidence interval, 1.03-4.84; P = .04), using the median of the MRS from the discovery cohort as the threshold. The MRS demonstrated a temporal validity by capturing individuals that developed CD up to 5 years before disease onset (area under the curve > 0.65). The 5 most important taxa contributing to the MRS included Ruminococcus torques, Blautia, Colidextribacter, an uncultured genus-level group from Oscillospiraceae, and Roseburia.

Conclusion: This study is the first to demonstrate that gut microbiome composition is associated with future onset of CD and suggests that gut microbiome is a contributor in the pathogenesis of CD.

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2023.05.032DOI Listing

Publication Analysis

Top Keywords

gut microbiome
28
microbiome composition
24
composition associated
12
gut
8
associated future
8
future onset
8
crohn's disease
8
healthy first-degree
8
first-degree relatives
8
composition
7

Similar Publications

Microbiome dysbiosis in reflux esophagitis has been extensively studied. However, limited research has examined microbiota across different segments of the upper gastrointestinal tract in reflux esophagitis. In this study, we investigated microbial alterations in three esophageal segments (upper, middle, and lower) and the gastric fundus of reflux esophagitis patients and healthy controls.

View Article and Find Full Text PDF

This study investigated the association between parameters derived from bioelectrical impedance spectroscopy (BIS) and arterial stiffness, as measured using carotid-femoral pulse wave velocity (cfPWV) and brachial-ankle pulse wave velocity (baPWV) pulse wave velocities. Data from 292 Japanese adults were analyzed. BIS was used to assess the phase angle (PhA), extracellular water to intracellular water ratio (ECW/ICW), and body cell mass-to-free fat mass ratio (BCM/FFM).

View Article and Find Full Text PDF

Background: Improving the efficacy of anti-programmed death 1 (PD-1) monoclonal antibody (mAb) therapy remains a major challenge for cancer immunotherapy in non-small cell lung cancer (NSCLC). Gut microbial metabolites can influence immunotherapy efficacy.

Methods: ELISA was used to compare the serum 5-hydroxyindoleacetic acid (5-HIAA) level in patients with NSCLC.

View Article and Find Full Text PDF

Introduction: Combined vascular endothelial growth factor/programmed death-ligand 1 blockade through atezolizumab/bevacizumab (A/B) is the current standard of care in advanced hepatocellular carcinoma (HCC). A/B substantially improved objective response rates compared with tyrosine kinase inhibitor sorafenib; however, a majority of patients will still not respond to A/B. Strong scientific rationale and emerging clinical data suggest that faecal microbiota transfer (FMT) may improve antitumour immune response on PD-(L)1 blockade.

View Article and Find Full Text PDF

Gut microbiome and mitochondrial crosstalk in Schizophrenia, a mental disability: Emerging mechanisms and therapeutic targets.

Neurosci Biobehav Rev

September 2025

Department of Biotechnology, Faculty of Science and Humanities, SRM Institute of Science and Technology, Kattankulathur, 603203, Chengalpattu District, Tamil Nadu, India. Electronic address:

Gut-mitochondria is an emerging paradigm in understanding the pathophysiology of complex neuropsychiatric disorders such as Schizophrenia (SCZ). This bidirectional communication network connects the gastrointestinal microbiota with mitochondrial function and brain health, offering novel insights into disease onset and progression. SCZ, characterized by hallucinations, delusions, cognitive impairments, and social withdrawal, has traditionally been attributed to genetic and neurochemical imbalances.

View Article and Find Full Text PDF